Pure Global

Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France - Trial NCT06421311

Access comprehensive clinical trial information for NCT06421311 through Pure Global AI's free database. This phase not specified trial is sponsored by Bristol-Myers Squibb and is currently Not yet recruiting. The study focuses on Urothelial Carcinoma. Target enrollment is 300 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06421311
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06421311
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France
Ambispective Observational Study of Muscle Invasive Urothelial Carcinoma Patients Treated With Adjuvant Nivolumab in France

Study Focus

Urothelial Carcinoma

nivolumab

Observational

drug

Sponsor & Location

Bristol-Myers Squibb

Strasbourg, France

Timeline & Enrollment

N/A

Jun 15, 2024

May 01, 2028

300 participants

Primary Outcome

Disease-free survival (DFS) of participants

Summary

This study will estimate the real-world effectiveness of adjuvant nivolumab therapy in adult
 participants with muscle invasive urothelial carcinoma (MIUC) in France.

ICD-10 Classifications

Carcinoma in situ: Other and unspecified urinary organs
Malignant neoplasm of ureter
Malignant neoplasms of urinary tract
Malignant neoplasm: Overlapping lesion of urinary organs
Malignant neoplasm: Urethra

Data Source

ClinicalTrials.gov

NCT06421311

Non-Device Trial